Histological Evaluation of Atrial Fibrillation Substrate Based on Atrial Septum Biopsy 3

Histological Evaluation of Atrial Fibrillation Substrate Based on Atrial Septum Biopsy 3 - HEAL-AF Study 3

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059261

Enrollment

Registered

2025-10-01

Start date

2023-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients are those who meet all of the following criteria: 1. Patients undergoing radiofrequency catheter ablation for recurrent atrial fibrillation or macroreentrant atrial tachycardia during the period from the date of issuance of the administrative approval notice until December 31, 2025. 2. Patients who previously participated in the HEAL-AF study, HEAL-AF2 study, or FUTURE-AF-S study, and who underwent atrial biopsy at the time of the prior ablation. 3. Age 20 years or older.

Exclusion criteria

Exclusion criteria: Exclusion Criteria 1. Pregnant patients or those with the possibility of pregnancy. 2. Patients with evidence of left atrial thrombus. 3. Patients deemed unsuitable for study participation by the attending physician.

Design outcomes

Primary

Measure	Time frame
Association between temporal histopathological changes and recurrence post-ablation	—

Secondary

Measure	Time frame
Relationship between histological findings and cardiovascular outcomes Associations between blood biomarkers and histological findings Associations between gene expression profiles and histological findings	—

Countries

Japan

Contacts

Public ContactTAKANORI YAMAGUCHI

Saga University Department of Cardiovascular Medicine

takanori@cc.saga-u.ac.jp0952342364

Outcome results